Authors' recommendations: Hepatitis C is a virus that causes inflammation of the liver. The virus is most commonly passed on by needles contaminated with infected blood, but it is also occasionally spread through unprotected sex. Most people with hepatitis C will have it for many years and they may or may not have symptoms. If the virus is untreated, it can lead to serious liver disease, such as liver cirrhosis and cancer. Current treatments of hepatitis C include a combination of drugs so that viral resistance doesn't develop to one specific drug. The combination of therapies used may depend on the type of hepatitis C virus, and some drugs require injection. Glecaprevir and pibrentasvir are two new drugs combined in a single tablet taken by mouth once a day for 8-12 weeks. Glecaprevir and pibrentasvir target different aspects of the hepatitis C virus and this drug combination aims to treat all known types of hepatitis C. Glecaprevir with pibrentasvir is being studied to determine how well it works and whether it is safe to use in those with hepatitis C infection. If licensed, glencaprevir with pibrentasvir will offer an injection free treatment option for patients with hepatitis C.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/glecaprevir-with-pibrentasvir-for-chronic-hepatitis-c-infection-genotypes-1-2-3-4-5-and-6/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)